The aim of this study is the safety and efficacy of irreversible electroporation (IRE) plus natural killer (NK) immunotherapy to recurrent liver cancer.
By enrolling patients with recurrent liver cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using IRE and NK cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
20
One kind of electric ablation machine from Angiodynamic company (USA)
Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
Fuda cancer institute of Fuda cancer hospital
Guangzhou, Guangdong, China
Relief degree of tumors
It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）
Time frame: 3 months
Progress free survival（PFS）
Time frame: 1 year
Overall survival（OS）
Time frame: 3 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.